- Home
- BWB vs ATAI Comparison
BWB vs ATAI Comparison
Compare BWB & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- ATAI
- Stock Information
- Founded
- BWB 2005
- ATAI 2018
- Country
- BWB United States
- ATAI Germany
- Employees
- BWB N/A
- ATAI N/A
- Industry
- BWB Major Banks
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- BWB Finance
- ATAI Health Care
- Exchange
- BWB Nasdaq
- ATAI Nasdaq
- Market Cap
- BWB 442.3M
- ATAI 444.7M
- IPO Year
- BWB 2018
- ATAI 2021
- Fundamental
- Price
- BWB $15.79
- ATAI $3.47
- Analyst Decision
- BWB Strong Buy
- ATAI Strong Buy
- Analyst Count
- BWB 2
- ATAI 3
- Target Price
- BWB $20.00
- ATAI $13.33
- AVG Volume (30 Days)
- BWB 56.0K
- ATAI 6.6M
- Earning Date
- BWB 07-23-2025
- ATAI 08-12-2025
- Dividend Yield
- BWB N/A
- ATAI N/A
- EPS Growth
- BWB 12.01
- ATAI N/A
- EPS
- BWB 1.21
- ATAI N/A
- Revenue
- BWB $119,312,000.00
- ATAI $1,863,000.00
- Revenue This Year
- BWB $31.47
- ATAI $423.05
- Revenue Next Year
- BWB $11.57
- ATAI N/A
- P/E Ratio
- BWB $13.27
- ATAI N/A
- Revenue Growth
- BWB 12.23
- ATAI 572.56
- 52 Week Low
- BWB $11.93
- ATAI $1.03
- 52 Week High
- BWB $17.66
- ATAI $4.00
- Technical
- Relative Strength Index (RSI)
- BWB 45.14
- ATAI 63.60
- Support Level
- BWB $15.94
- ATAI $3.06
- Resistance Level
- BWB $16.70
- ATAI $3.70
- Average True Range (ATR)
- BWB 0.44
- ATAI 0.28
- MACD
- BWB -0.09
- ATAI 0.01
- Stochastic Oscillator
- BWB 15.67
- ATAI 62.68
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.